The U.S. OTC continuous glucose monitoring (CGM) devices market size was valued at USD 194.0 million in 2025 and is projected to grow from USD 207.2 million in 2026 to USD 403.5 million by 2033, at a CAGR of 9.6% from 2026 to 2033. The rising adoption of lifestyle wellness devices, including CGM to ease diabetes management, and easy access to wearable health tools, are fueling demand. In 2025, nearly 20% of Americans planned to use wearable devices to achieve their health goals, while Abbott reported that two out of three U.S. Lingo members began using an OTC CGM to make healthier decisions in real time.
In the coming 5 to 10 years, the adoption rate is expected to reach 50% among elderly Americans. The growing geriatric population and sedentary lifestyles contribute to the disease burden, imposing the development of advanced monitoring solutions such as CGM. Furthermore, expanding healthcare infrastructure and distribution of CGM devices through e-commerce without a prescription would ease accessibility. Technological advancements like sensor accuracy, app integration, and data sharing further support market growth across urban and semi-urban areas.
As of 2025, nearly 38 million American adults are diagnosed with diabetes, marking 11.5% of the total adult population in the U.S. Furthermore, around 97 million adults are prediabetic in the country. Obesity and a sedentary lifestyle are the major contributing factors to the prevalence of diabetes. Continued surge in type 2 diabetes cases and growing awareness of early diagnoses are likely to boost the demand for OTC CGM devices in the U.S.
Newly introduced OTC CGM devices are suggested to be used by type 2 diabetes that are not on insulin. As type 2 diabetes does not get the insurance for prescription CGM, OTC comes in as a help. OTC CGM sells at an affordable rate and without a prescription. Although the OTC CGMs are not covered by insurance, the HAS/FSA funds are generally accepted.
This product will be delivered within 1-3 business days.
In the coming 5 to 10 years, the adoption rate is expected to reach 50% among elderly Americans. The growing geriatric population and sedentary lifestyles contribute to the disease burden, imposing the development of advanced monitoring solutions such as CGM. Furthermore, expanding healthcare infrastructure and distribution of CGM devices through e-commerce without a prescription would ease accessibility. Technological advancements like sensor accuracy, app integration, and data sharing further support market growth across urban and semi-urban areas.
As of 2025, nearly 38 million American adults are diagnosed with diabetes, marking 11.5% of the total adult population in the U.S. Furthermore, around 97 million adults are prediabetic in the country. Obesity and a sedentary lifestyle are the major contributing factors to the prevalence of diabetes. Continued surge in type 2 diabetes cases and growing awareness of early diagnoses are likely to boost the demand for OTC CGM devices in the U.S.
Newly introduced OTC CGM devices are suggested to be used by type 2 diabetes that are not on insulin. As type 2 diabetes does not get the insurance for prescription CGM, OTC comes in as a help. OTC CGM sells at an affordable rate and without a prescription. Although the OTC CGMs are not covered by insurance, the HAS/FSA funds are generally accepted.
U.S. OTC Continuous Glucose Monitoring (CGM) Devices Market Report Segmentation
This report forecasts revenue growth at the country level and analyzes the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. OTC continuous glucose monitoring (CGM) devices market report based on user, application, and sales channel.User Outlook (Revenue, USD Million, 2021 - 2033)
- Non-diabetic
- Prediabetic
- Diabetic
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Lifestyle Wellness
- Diabetes Monitoring
Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Company Website
- Retailers
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. OTC CGM Devices Market Variables, Trends, & Scope
Chapter 4. U.S. OTC CGM Devices Market: User Estimates & Trend Analysis
Chapter 5. U.S. OTC CGM Devices Market: Application Estimates & Trend Analysis
Chapter 6. U.S. OTC CGM Devices Market: Sales Channel Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Abbott Laboratories
- Dexcom Inc.
